2-(哒嗪-4-基)噻唑-4-羧酸 | 955400-58-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(哒嗪-4-基)噻唑-4-羧酸
• 英文名称: 2-(pyridazin-4-yl)-1,3-thiazole-4-carboxylic acid
• 英文别名: 2-(Pyridazin-4-yl)thiazole-4-carboxylic acid；2-pyridazin-4-yl-1,3-thiazole-4-carboxylic acid
• CAS: 955400-58-5
• 化学式: C₈H₅N₃O₂S
• 分子量: 207.213
• InChiKey: TVEWUGABIVCMQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-(哒嗪-4-基)噻唑-4-羧酸 、 tert-butyl ({(3S)-1-[6-amino-3-phenoxy-2-(trifluoromethyl)phenyl]piperidin-3-yl}methyl)carbamate 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以5.85 g的产率得到tert-butyl N-[[(3S)-1-[3-phenoxy-6-[(2-pyridazin-4-yl-1,3-thiazole-4-carbonyl)amino]-2-(trifluoromethyl)phenyl]piperidin-3-yl]methyl]carbamate
  参考文献：
  名称：

  US2022/315603

  摘要：

  公开号：
• 作为产物：
  描述：

  2-(哒嗪-4-基)噻唑-4-羧酸乙酯 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 2-(哒嗪-4-基)噻唑-4-羧酸
  参考文献：
  名称：

  WO2008/54702

  摘要：

  公开号：

文献信息

• FAAH INHIBITORS
  申请人：Sprott Kevin

  公开号：US20090118503A1

  公开（公告）日：2009-05-07

  Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  本文描述了可用于治疗疼痛、炎症和其他病症的吲哚衍生物。其中某些化合物是苄基衍生物，而其他化合物是苯甲酰基衍生物。这些化合物至少在吲哚的3位被取代。
• USEFUL INDOLE COMPOUNDS
  申请人：Bartolini Wilmin

  公开号：US20090264653A1

  公开（公告）日：2009-10-22

  Indoles that have activity as inhibitors of FAAH are described as are indoles and indole derivatives that have activity as inhibitors of DAO.

  本文描述了具有FAAH抑制剂活性的吲哚化合物，以及具有DAO抑制剂活性的吲哚及其衍生物。
• AZOLECARBOXAMIDE DERIVATIVE
  申请人：Sugasawa Keizo

  公开号：US20090286766A1

  公开（公告）日：2009-11-19

  Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

  提供了一种用于治疗或预防与过度活跃膀胱、下泌尿道疾病（如间质性膀胱炎和慢性前列腺炎伴随下泌尿道疼痛）以及伴随疼痛的各种疾病相关的尿频、尿急和尿失禁的药剂。一种新型的唑烷羧酰胺衍生物，其中唑环（如硫唑环或噁唑环）通过羧酰胺键连接到苯环、吡啶环或嘧啶环上，被证实具有强效的trkA受体抑制活性，并被发现是一种用于治疗或预防下泌尿道疾病和伴随疼痛的各种疾病的药剂，其疗效和安全性优异，因此本发明得以完成。
• INDOLE COMPOUNDS
  申请人：Talley John Jeffrey

  公开号：US20100197708A1

  公开（公告）日：2010-08-05

  Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.

  本文介绍了用于治疗疼痛、炎症和其他疾病的吲哚衍生物。其中某些化合物是苄基衍生物，而其他化合物是苯甲酰基衍生物。这些化合物至少在吲哚的3位被取代。
• ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Shipps, JR. Gerald W.

  公开号：US20120328691A1

  公开（公告）日：2012-12-27

  The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.

  本发明涉及式（I）的新型苯胺哌嗪衍生物，包含该苯胺哌嗪衍生物的组合物，以及使用该苯胺哌嗪衍生物治疗或预防增生性疾病、癌症、抗增生性疾病、炎症、关节炎、中枢神经系统疾病、心血管疾病、脱发、神经疾病、缺血性损伤、病毒性疾病、真菌感染或与蛋白激酶活性相关的疾病的方法。